A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Table of Contents
Clinical Ovarian and Other Gynecologic Cancer
Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease relapsed during or within 6 months after completion of platinum-based therapy received the novel microtubuletargeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this difficultto-treat population. 60 Improved 8 -Year Survival for Patientsdoi:10.1016/s2212-9553(14)00007-6 fatcat:rfx5f2gtxrg6den7c3vxzq355q